Trial Profile

An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esketamine (Primary)
Indications Major depressive disorder
Focus Adverse reactions; Therapeutic Use
Acronyms SUSTAIN-3
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

05 Sep 2023 According to a Janssen media release, sub-group analysis of this trial will be presented at the Psych Congress 2023.
09 Aug 2023 Interim results of subgroup analysis (n=32) assessing Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period published in the CNS Drugs
28 Feb 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com